1. Home
  2. NGNE vs FSBW Comparison

NGNE vs FSBW Comparison

Compare NGNE & FSBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NGNE
  • FSBW
  • Stock Information
  • Founded
  • NGNE 2003
  • FSBW 1936
  • Country
  • NGNE United States
  • FSBW United States
  • Employees
  • NGNE N/A
  • FSBW N/A
  • Industry
  • NGNE Biotechnology: Pharmaceutical Preparations
  • FSBW Banks
  • Sector
  • NGNE Health Care
  • FSBW Finance
  • Exchange
  • NGNE Nasdaq
  • FSBW Nasdaq
  • Market Cap
  • NGNE 325.3M
  • FSBW 324.8M
  • IPO Year
  • NGNE N/A
  • FSBW 2012
  • Fundamental
  • Price
  • NGNE $18.48
  • FSBW $42.71
  • Analyst Decision
  • NGNE Strong Buy
  • FSBW Hold
  • Analyst Count
  • NGNE 7
  • FSBW 1
  • Target Price
  • NGNE $41.86
  • FSBW $44.00
  • AVG Volume (30 Days)
  • NGNE 110.1K
  • FSBW 17.5K
  • Earning Date
  • NGNE 08-11-2025
  • FSBW 10-21-2025
  • Dividend Yield
  • NGNE N/A
  • FSBW 2.62%
  • EPS Growth
  • NGNE N/A
  • FSBW N/A
  • EPS
  • NGNE N/A
  • FSBW 4.15
  • Revenue
  • NGNE N/A
  • FSBW $139,676,000.00
  • Revenue This Year
  • NGNE N/A
  • FSBW $9.62
  • Revenue Next Year
  • NGNE N/A
  • FSBW $5.35
  • P/E Ratio
  • NGNE N/A
  • FSBW $10.28
  • Revenue Growth
  • NGNE N/A
  • FSBW 0.61
  • 52 Week Low
  • NGNE $6.88
  • FSBW $34.61
  • 52 Week High
  • NGNE $74.49
  • FSBW $49.15
  • Technical
  • Relative Strength Index (RSI)
  • NGNE 35.93
  • FSBW 61.80
  • Support Level
  • NGNE $19.59
  • FSBW $41.40
  • Resistance Level
  • NGNE $20.46
  • FSBW $42.89
  • Average True Range (ATR)
  • NGNE 1.23
  • FSBW 1.14
  • MACD
  • NGNE -0.20
  • FSBW 0.32
  • Stochastic Oscillator
  • NGNE 13.37
  • FSBW 95.42

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About FSBW FS Bancorp Inc.

FS Bancorp Inc is the holding company of 1st Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.

Share on Social Networks: